KRT23 SEBAGAI BIOMARKER PROGNOSTIK PADA ADENOKARSINOMA REKTAL: ANALISIS BIOINFORMATIKA BERBASIS UALCAN: KRT23 sebagai Biomarker Prognostik pada Adenokarsinoma Rektal: Analisis Bioinformatika Berbasis UALCAN

Danang Prasetyaning Amukti; Mitha Dwi Puspitasari; Ari Widhiarso; Bayu Bakti Angga Santoso; Ria Indah Pratami

doi:10.46772/jophus.v7i2.1836

Authors

Danang Prasetyaning Amukti Universitas Alma Ata
Mitha Dwi Puspitasari Alma Ata University
Ari Widhiarso Alma Ata University
Bayu Bakti Angga Santoso Alma Ata University
Ria Indah Pratami ahmad dahlan university

DOI:

https://doi.org/10.46772/jophus.v7i2.1836

Keywords:

Rectum Adenocarcinoma, READ, UALCAN, KRT23, Bioinformatics

Abstract

Introduction: Colorectal cancer, including READ, is one of the leading causes of cancer death worldwide. Recent studies have shown the involvement of the KRT23 gene, a member of the type I keratin family, in various malignant processes, including tumor cell proliferation, migration, and invasion. Although KRT23 expression has been studied in several types of cancer, its role in rectal cancer remains poorly understood. This study aimed to evaluate the relationship between KRT23 expression and patients' clinical characteristics and their survival. Methods: KRT23 expression data in rectal cancer patients were obtained from the UALCAN platform, which included subgroups based on race, sex, and weight status. Analysis was performed to evaluate the relationship between KRT23 expression levels and patients' clinical characteristics and their effects on survival using Kaplan-Meier curves and log-rank statistical analysis. Results: KRT23 expression was significantly increased in rectal cancer tissues compared to normal tissues. Survival analysis showed that race significantly affected the relationship between KRT23 expression and patient prognosis (p < 0.0001), especially in the Caucasian and African-American racial groups. In contrast, there was no significant difference based on gender (p = 0.97) and weight status (p = 0.64). Conclusion: High KRT23 expression is associated with better prognosis in certain racial subgroups, making it a potential candidate prognostic biomarker for rectal cancer. However, further studies with larger sample sizes are needed to strengthen these findings and understand the underlying biological mechanisms.

References

[1] “Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023 Feb;72(2):338-344. doi: 10.1136/gutjnl-2022-327736”.

[2] “Rezkitha YAA, Panenggak NSR, Lusida MI, Rianda RV, Mahmudah I, Pradana AD, Uchida T, Miftahussurur M. Detecting colorectal cancer using genetic and epigenetic biomarkers: screening and diagnosis. J Med Life. 2024 Jan;17(1):4-14. doi: 10.25122/jml-2023-0269”.

[3] “Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021 Mar 17;134(7):783-791. doi: 10.1097/CM9.0000000000001474”.

[4] “Zhu L, Ling C, Xu T, Zhang J, Zhang Y, Liu Y, Fang C, Yang L, Zhuang W, Wang R, Ping J, Wang M. Clinicopathological Features and Survival of Signet-Ring Cell Carcinoma and Mucinous Adenocarcinoma of Right Colon, Left Colon, and Rectum. Pathol Oncol Res. 2021 Jul 2;27:1609800. doi: 10.3389/pore.2021.1609800. PMID: 34276258; PMCID: PMC8283508.”.

[5] “Lin A, Zhang J, Luo P. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Front Immunol. 2020 Aug 12;11:2039. doi: 10.3389/fimmu.2020.02039 ”.

[6] L. M. Irham et al., “Applied of bioinformatics in drug discovery and drug development: Bioinformatic analysis 1996-2024,” BIO Web Conf., vol. 148, p. 01003, Jan. 2024, doi: 10.1051/bioconf/202414801003.

[7] G. Gumelar et al., “Harnessing Genomic and Bioinformatic Data to Broaden Understanding of Leukaemia Across Continents,” Scripta Medica (Banja Luka), vol. 55, no. 6, pp. 717–725, Nov. 2024, doi: 10.5937/scriptamed55-51720.

[8] “Piccinno E, Scalavino V, Labarile N, Armentano R, Giannelli G, Serino G. miR-195-5p Inhibits Colon Cancer Progression via KRT23 Regulation. Pharmaceutics. 2024 Dec 4;16(12):1554. doi: 10.3390/pharmaceutics16121554”.

[9] “Ren M, Gao Y, Chen Q, Zhao H, Zhao X, Yue W. The Overexpression of Keratin 23 Promotes Migration of Ovarian Cancer via Epithelial-Mesenchymal Transition. Biomed Res Int. 2020 Nov 1;2020:8218735. doi: 10.1155/2020/8218735”.

[10] “Kingnate C, Charoenkwan K, Kumfu S, Chattipakorn N, Chattipakorn SC. Possible Roles of Mitochondrial Dynamics and the Effects of Pharmacological Interventions in Chemoresistant Ovarian Cancer. EBioMedicine. 2018 Aug;34:256-266. doi: 10.1016/j.ebiom.2018.07.026. Epub 2018 Jul 23”.

[11] “Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017 Aug;19(8):649-658. doi: 10.1016/j.neo.2017.05.002”.

[12] “Li J, Ran H, Zeng X, Yang D, Zeng X, Zhang P. Identification of HOXB9 based on comprehensive bioinformatics analysis for predicting prognosis of head and neck squamous cell carcinoma. Medicine (Baltimore). 2023 Sep 1;102(35):e35035. doi: 10.1097/MD.0000000000035035”.

[13] “Qiu Z, Xin M, Wang C, Zhu Y, Kong Q, Liu Z. Pan-Cancer Analysis of Microfibrillar-Associated Protein 2 (MFAP2) Based on Bioinformatics and qPCR Verification. J Oncol. 2022 Feb 15;2022:8423173. doi: 10.1155/2022/8423173”.

[14] “Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, Creighton CJ, Varambally S. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022 Mar;25:18-27. doi: 10.1016/j.neo.2022.01.001”.

[15] “Liu Z, Zhou J, Wang Z, Zhou Z. Analysis of SEC24D Gene in Breast Cancer Based on UALCAN Database. Open Life Sci. 2019 Dec 31;14:707-711. doi: 10.1515/biol-2019-0080”.

[16] “Liang M, Lai T, Li Z, Yu W, Cao M, Yao N, Hu Y, Liu T, Liang J. GINS1 is a prognostic biomarker and correlated with methylation and immune escape in liver hepatocellular carcinoma. Front Oncol. 2025 Mar 7;15:1492599. doi: 10.3389/fonc.2025.1492599”.

[17] “Humolungo DT, Anjani R, Irham LM, Sulistyani N, Ma’ruf M, Amukti DP, Adikusuma W, Sarasmita MA, Khairi S, Purwanto BD, Suyatmi S. Identification of pathogenic gene variants in carpal tunnel syndrome using bioinformatics approaches. InE3S Web of Conferences 2024 (Vol. 501, p. 01022). EDP Sciences.”.

[18] L. M. Irham et al., “Trends in drug repurposing for chronic hepatitis-B infection:bibliometric-basedapproach1990-2024,” in BIO Web of Conferences, EDP Sciences, Jan. 2025. doi: 10.1051/bioconf/202414804003.

[19] “Lavoro A, Falzone L, Gattuso G, Conti GN, Caltabiano R, Madonna G, Capone M, McCubrey JA, Ascierto PA, Libra M, Candido S. Identification of SLC22A17 DNA methylation hotspot as a potential biomarker in cutaneous melanoma. J Transl Med. 2024 Oct 2;22(1):887. doi: 10.1186/s12967-024-05622-9”.

[20] D. Amikti and Ria Indah Pratami, “Analisis Bioinformatika Ekspresi MIER3 sebagai Biomarker Potensial dan Target Terapeutik pada Kanker Esofagus,” JURNAL FARMASI GALENIKA, vol. 12, no. 2, pp. 89–102, Aug. 2025, doi: 10.70410/jfg.v12i2.389.

[21] R. Gustinanda et al., “CURRENT TOPIC Trend of Non-Hodgkin Lymphoma Research Using a Genomics-Based Approach: A Bibliometric Analysis From 1985-2024,” Scr Med, vol. 56, no. 6, pp. 1217–1244, 2025, doi: 10.5937/scriptamed56-58095.

[22] R. Indah Pratami and D. Prasetyaning Amukti, “ANALISIS EKSPRESI MMP1 PADA KARSINOMA PAYUDARA INVASIF DENGAN BIOINFORMATIKA MELALUI UALCAN: BIOMARKER PROGNOSTIK POTENSIAL,” Journal of Pharmacy UMUS, vol. 7, no. 01, pp. 42–51, 2025.

[23] D. Amukti et al., “Tren Global Penelitian Toll-like receptor 4 pada Penyakit Kardiovaskular: Analisis Bibliometrik 2017-2025,” INPHARNMED Journal (Indonesian Pharmacy and Natural Medicine Journal), vol. 9, no. 1, p. 1, Aug. 2025, doi: 10.21927/inpharnmed.v9i1.5989.

[24] D. Prasetyaning Amukti, R. I. Pratami, D. Farida Ismyama, A. Puspitasari, and T. Herlina, “Pharmaceutical and Clinical Journal of Nusantara (PCJN) Pharmacogenomic and Bioinformatic Insights into ACE Gene Variants and Their Influence on ACE Inhibitor Response in Hypertension,” Pharmaceutical and Clinical Journal of Nusantara, doi: 10.58549/pcjn.v3i02.113.

[25] “Zhang N, Zhang R, Zou K, Yu W, Guo W, Gao Y, Li J, Li M, Tai Y, Huang W, Song C, Deng W, Cui X. Keratin 23 promotes telomerase reverse transcriptase expression and human colorectal cancer growth. Cell Death Dis. 2017 Jul 27;8(7):e2961. doi: 10.1038/cddis.2017.339”.

[26] “Sheta M, Yoshida K, Kanemoto H, Calderwood SK, Eguchi T. Stress-Inducible SCAND Factors Suppress the Stress Response and Are Biomarkers for Enhanced Prognosis in Cancers. Int J Mol Sci. 2023 Mar 8;24(6):5168. doi: 10.3390/ijms24065168”.

[27] “Ors-Kumoglu G, Gulce-Iz S, Biray-Avci C. Therapeutic microRNAs in human cancer. Cytotechnology. 2019 Feb;71(1):411-425. doi: 10.1007/s10616-018-0291-8”.

[28] “Kawai H, Saito Y, Suzuki Y. Gender differences in the correlation between prognosis and postoperative weight loss in patients with non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2017 Aug 1;25(2):272-277. doi: 10.1093/icvts/ivx092”.

[29] “Aravindhan S, Younus LA, Hadi Lafta M, Markov A, Ivanovna Enina Y, Yushchenkо NA, Thangavelu L, Mostafavi SM, Pokrovskii MV, Ahmadi M. P53 long noncoding RNA regulatory network in cancer development. Cell Biol Int. 2021 Aug;45(8):1583-1598. doi: 10.1002/cbin.11600”.

[30] “Pham TH, Park HM, Kim J, Hong JT, Yoon DY. STAT3 and p53: Dual Target for Cancer Therapy. Biomedicines. 2020 Dec 21;8(12):637. doi: 10.3390/biomedicines8120637”.

[31] “Ren M, Gao Y, Chen Q, Zhao H, Zhao X, Yue W. The Overexpression of Keratin 23 Promotes Migration of Ovarian Cancer via Epithelial-Mesenchymal Transition. Biomed Res Int. 2020 Nov 1;2020:8218735. doi: 10.1155/2020/8218735”.

KRT23 SEBAGAI BIOMARKER PROGNOSTIK PADA ADENOKARSINOMA REKTAL: ANALISIS BIOINFORMATIKA BERBASIS UALCAN